Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition

United States News News

Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition
United States Latest News,United States Headlines
  • 📰 CNBC
  • ⏱ Reading Time:
  • 30 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 72%

Bristol Myers Squibb’s revenue was in line with estimates, but fell slightly from the same period last year due to lower sales of blood cancer drug Revlimid.

Bristol Myers Squibb reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates.Bristol Myers Squibb

The drugmaker said that decline was due to lower sales of Revlimid, which generated $1.43 billion for the quarter. Bristol Myers has been under pressure to launch or acquire new drug products as Revlimid – and eventually, otherRevlimid sales, which fell 41% from the third quarter of 2022, also dropped due to an increase in patients receiving the drug at no cost through the company's patient assistance foundation, Bristol Myers said.

The company narrowed its full-year adjusted earnings outlook to $7.50 to $7.65 per share, from a previous forecast of $7.35 to $7.65 a share.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CNBC /  🏆 12. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Bristol-Myers Squibb earnings top estimatesBristol-Myers Squibb earnings top estimatesCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Read more »

Bristol Myers says it needs another year to hit target for new drugsBristol Myers says it needs another year to hit target for new drugsDrugmaker Bristol Myers Squibb (BMY.N) on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia treatment Reblozyl, psoriasis drug Sotyktu, and multiple sclerosis drug Zeposia takes longer than expected.
Read more »

Turning Michael Myers Into a Supernatural Cult Monster Made Him Less ScaryTurning Michael Myers Into a Supernatural Cult Monster Made Him Less ScaryHalloween: The Curse of Michael Myers introduces the Cult of Thorn and tries to give the iconic killer an unneeded backstory.
Read more »

De La Ghetto, Bryant Myers, Luar La L & YOVNGCHIMI Debut on Hot 100De La Ghetto, Bryant Myers, Luar La L & YOVNGCHIMI Debut on Hot 100All 21 songs from Bad Bunny’s new LP chart on the Hot 100.
Read more »

Longtime fisherman reflects on his career in Bristol BayLongtime fisherman reflects on his career in Bristol BayDan Barr is eighty-one and a half years old. He fished Bristol Bay for just about half his life.
Read more »

NECA's Tom Atkins Halloween III: Season of the Witch Figure Is Boozy PerfectionNECA's Tom Atkins Halloween III: Season of the Witch Figure Is Boozy PerfectionDr. Dan Challis, as well as a new Michael Myers and Freddy Krueger, highlight the toy company's spooky new drop.
Read more »



Render Time: 2025-02-19 17:06:55